Windlas Biotech H1 FY27 Revenue Crosses ₹500 Cr
Windlas Biotech reported its H1 and Q2 FY27 unaudited financial results, marking its 15th consecutive quarter of record revenue. For H1 FY27, revenue reached ₹512 crores, an 18% YoY increase, with Adjusted EBITDA at ₹70 crores (up 23% YoY) and Adjusted PAT at ₹50 crores (up 33% YoY). Q2 FY27 revenue stood at ₹264 crores, a 19% YoY growth, with Adjusted EBITDA of ₹36 crores and Adjusted PAT of ₹25 crores. The company achieved its highest ever EPS of ₹17.21 in H1 FY27. Plant 6 was commercialized in September 2026, and Plant-4 & Plant-5 received EUGMP certification. The company maintained strong net liquidity of ₹223 crores and is net debt-free. ROCE and ROE were reported at 38% and 33% respectively for H1 FY27 (excluding Plant 6).
Key Highlights
- H1 FY27 revenue crossed ₹500 Cr milestone, reaching ₹512 Cr.
- 15th consecutive quarter of record revenue reported.
- Adjusted PAT grew 33% YoY to ₹50 Cr in H1 FY27.
- Plant 6 commercialized; EUGMP certification received for Plants 4 & 5.
- Net liquidity stands strong at ₹223 Cr; company is net debt-free.
Price Impact
More from WINDLAS